Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective Study on 18F-DCFPyL PET/CT Imaging in Biochemical Recurrence of Prostate Cancer

Next Previous
Trial Profile

A Prospective Study on 18F-DCFPyL PET/CT Imaging in Biochemical Recurrence of Prostate Cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Piflufolastat F18 (Primary) ; Fluorocholine 18F
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Diagnostic use
  • Acronyms PYTHON
  • Sponsors Curium Pharma; Cyclopharma

Most Recent Events

  • 22 Feb 2024 According to a Curium Pharma media release, based on results from the Phase III PYTHON, OSPREY and CONDOR trial, the imaging AG on 31 January 2024 has submitted marketing authorization application for PYLCLARI (INN: Piflufolastat (18F) formerly known as (18F)-DCFPyL) to the Swiss Agency for Therapeutic Products (Swissmedic) which has been accepted for evaluation.
  • 21 Jul 2023 Primary endpoint has been met. (to compare per-patient detection rate of 18F-DCFPyL PET/CT versus that of 18F-FCH PET/CT.), according to a Curium Pharma media release.
  • 21 Jul 2023 According to a Curium Pharma media release, results from this study were published online ahead of print in the European Journal of Nuclear Medicine and Molecular Imaging in June 2023. Dr. Daniela E. Oprea-Lager lead author of the PYTHON Manuscript submitted.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top